Business
Personalis Reports First Quarter 2025 Financial Results
Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year FREMONT, Calif.--(BUSINESS
About this update from Personalis, Inc.
[{"type":"text","content":"\nClinical test volume of 2,184 increased 52% sequentially\n\nPharma tests and services of $13.6 million increased 39% year-over-year\n\n FREMONT, Calif.--(BUSINESS WIRE)--\nPersonalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights.\n\nRecent Business Highlights\n\n\nDelivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis’ technology\n\n\nHighlighted compelling performance of NeXT Personal for resectable Stage I-IV colorectal cancer (CRC) in a study of 71 patients with British Columbia Cancer and an oral presentation at the American Association for Cancer Research (AACR) in Chicago in April\n\n\n100% of patients that eventually recurred were detected as ctDNA positive by NeXT Personal, prior to detection on imaging\n\n\n87% of eventual clinical recurrences were detectable within the early landmark window, 2 to 8 weeks after surgery, with 85% detectable by 4 weeks\n\n\n64% of the positive detections in the landmark window were in the ultrasensitive range, below 100 parts per million\n\n\n100% of challenging distant metastatic recurrences prior to imaging were detected, including lung metastasis\n\n\n\n\nPublished pivotal breast cancer study (Royal Marsden) using NeXT Personal in the Annals of Oncology and dossier submission was made to Medicare for reimbursement in early-stage breast cancer\n\n\nPublished results from TRACERx study in Nature Medicine, showing ctDNA levels linked to lung cancer recurrence and highlighting NeXT Personal®’s detection in early-stage patients\n\n\n“This year is off to a great start, with strong first quarter testing growth, and we remain confident that our “Win-in-MRD” strategy is working,” said Chris Hall, Chief Executive Officer and President. “We crossed the milestone of 2,000 tests delivered and submitted breast cancer data for Medicare coverage with expectations of a favorable outcome by the end of the year. In addition, we showed compelling clinical evidence in colorectal cancer suggesting our ultrasensitive approach can provide a leap in performance. We are pleased with how rapidly NeXT Personal is gro...